GlaxoSmithKline Pharmaceuticals Limited — Investor Meet, 16-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Pharmaceuticals' Q3 FY26 revenue crossed ₹1,000 Cr for the first time, growing 8.1% (standalone). EBITDA margin hit 35.9% (+520 bps) and PAT margin 27.3%, reflecting strong performance. General medicines and pediatric vaccines (+11%) drove growth, alongside the new oncology portfolio. Notably, a regulatory approval expanded eligibility for first-line endometrial cancer treatment. Supply constraints from prior quarters are now resolved, boosting future growth. Management aims to double the business to ₹8,000 Cr in 5-7 years, targeting 12-14% annual growth through innovation in oncology and liver disease, while sustaining current margins. The company is strategically positioned for accelerated growth.